Similar articles

• Bone scintigraphy and serum phosphatases in the detection and follow-up of bone metastases in prostatic cancer.

  Liewendahl K, Alfthan O, Ikonen T, Ruutu M, Rannikko S. Liewendahl K, et al. Scand J Urol Nephrol. 1984;18(3):181-5. doi: 10.3109/00365598409180181. Scand J Urol Nephrol. 1984. PMID: 6494827
• Contribution of bone scintigraphy, prostatic acid phosphatase and prostate-specific antigen to the monitoring of prostatic cancer.

  Hetherington JW, Siddall JK, Cooper EH. Hetherington JW, et al. Eur Urol. 1988;14(1):1-5. doi: 10.1159/000472885. Eur Urol. 1988. PMID: 2449352
• [Correlation between extent of metastatic lesions in whole body bone scintigraphy of patients with prostatic cancer and prostatic acid phosphatase (PAP) in blood by PAP RIA kit "EIKEN" (author's transl)].

  Kida T, Higuchi Y. Kida T, et al. Kaku Igaku. 1981 Aug;18(7):907-15. Kaku Igaku. 1981. PMID: 7321322 Japanese. No abstract available.
• [Bone scintigraphy for diagnosis of bone metastasis in patients with prostatic cancer].

  Nakashima J. Nakashima J. Nihon Rinsho. 2002 Dec;60 Suppl 11:135-9. Nihon Rinsho. 2002. PMID: 12599559 Review. Japanese. No abstract available.
• Proceedings: Diagnosis and staging of prostatic carcinoma.

  Prout GR Jr. Prout GR Jr. Cancer. 1973 Nov;32(5):1096-103. doi: 10.1002/1097-0142(197311)32:5<1096::aid-cncr2820320514>3.0.co;2-k. Cancer. 1973. PMID: 4202187 Review. No abstract available.